Genmab AS (MEX:GMABN) Cyclically Adjusted FCF per Share: MXN142.33 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GMABN Genmab AS MEX:GMABN
93 GF Score
Price MXN5,000.66
GF Value MXN5,659.54
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted FCF per Share?

Genmab AS MEX:GMABN 93 Cyclically Adjusted FCF per Share is MXN142.33 as of Jun. 2026. GuruFocus rates MEX:GMABN with a GF Score™ of 93/100 and a GF Value™ of MXN5,659.54 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Genmab AS's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN13.572. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN142.33 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted FCF Growth Rate was 16.20% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 32.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 34.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Genmab AS was 110.70% per year. The lowest was 32.70% per year. And the median was 52.10% per year.

As of today (2026-08-14), Genmab AS's current stock price is MXN5000.66. Genmab AS's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN142.33. Genmab AS's Cyclically Adjusted Price-to-FCF of today is 35.13.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Genmab AS was 24633.33. The lowest was 22.87. And the median was 128.95.


Genmab AS  (MEX:GMABN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=5000.66/142.33
=35.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Genmab AS was 24633.33. The lowest was 22.87. And the median was 128.95.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Genmab AS Cyclically Adjusted FCF per Share Related Terms


Genmab AS Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted FCF per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.43 80.68 93.89 171.20 173.49

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 180.03 161.85 173.49 167.30 142.33

MEX:GMABN vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted Price-to-FCF falls into.


MEX:GMABN
93GF Score
Genmab AS MEX:GMABN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=13.572/122.9700*122.9700
=13.572

Current CPI (Jun. 2026) = 122.9700.

Genmab AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 9.634 100.200 11.823
201612 -6.038 100.300 -7.403
201703 32.678 101.200 39.708
201706 24.976 101.200 30.349
201709 2.292 101.800 2.769
201712 12.788 101.300 15.524
201803 21.069 101.700 25.475
201806 4.297 102.300 5.165
201809 -9.170 102.400 -11.012
201812 8.589 102.100 10.345
201903 29.702 102.900 35.495
201906 8.249 102.900 9.858
201909 10.771 102.900 12.872
201912 7.311 102.900 8.737
202003 97.723 103.300 116.331
202006 7.039 103.200 8.387
202009 270.345 103.500 321.201
202012 -26.594 103.400 -31.627
202103 56.494 104.300 66.607
202106 14.175 105.000 16.601
202109 16.172 105.800 18.797
202112 6.057 106.600 6.987
202203 24.009 109.900 26.864
202206 36.581 113.600 39.598
202209 72.500 116.400 76.592
202212 23.704 115.900 25.150
202303 125.493 117.300 131.559
202306 12.134 116.400 12.819
202309 68.683 117.400 71.942
202312 64.908 116.700 68.395
202403 54.638 118.400 56.747
202406 60.732 118.500 63.023
202409 90.262 118.900 93.352
202412 115.969 118.900 119.939
202503 82.237 120.200 84.132
202506 15.794 120.700 16.091
202509 157.808 121.600 159.586
202512 82.160 121.200 83.360
202603 -0.565 121.680 -0.571
202606 13.572 122.970 13.572

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN142.33 mean?
Genmab AS (MEX:GMABN) has a Cyclically Adjusted FCF per Share of MXN142.33 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted FCF per Share too high?
Genmab AS's current Cyclically Adjusted FCF per Share is MXN142.33. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted FCF per Share of MXN142.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted FCF per Share is MXN142.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,659.54, compared to a current price of MXN5,000.66 — trading 11.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN142.33. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Cyclically Adjusted FCF per Share is MXN142.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (MEX:GMABN) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of MXN5,000.66 is trading 11.6% below its estimated GF Value™ of MXN5,659.54. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for MEX:GMABN:

  • Cyclically Adjusted FCF per Share: MXN142.33
  • GF Value™: MXN5,659.54 vs. price of MXN5,000.66 (11.6% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for MEX:GMABN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN5,000.66
Price
MXN5,659.54
GF Value